Aaron Cote
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aaron Cote has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Chengbei Li
Merck & Co., Inc
1 shared publication - Chenguang Liang
Process Research & Development, MRL, Merck & Co., Inc., Rahway, NJ, USA
1 shared publication - Guangli Hu
Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc, Rahway, USA
1 shared publication - Jeffrey C. Givand
Merck & Co., Inc
1 shared publication - Jing Song
Merck & Co., Inc
1 shared publication - Jingzhou Wang
Merck & Co., Inc
1 shared publication
Latest Publications
- Open Access
- 16 August 2026
- Published by Wiley in Biotechnology and Bioengineering
Purification of Disassembled Capsid Protein by Hydroxyapatite Chromatography Enhances Virus‐Like Particle Recovery
Virus‐like particles (VLPs) are a promising modality with extensive applications in prophylactic and therapeutic vaccine design. Human Papillomavirus (HPV) vaccines are one such example where VLP vaccine applications have led to the successful reduction in HPV‐associated diseases, such as cervical cancer. Current purification approaches utilize hydroxyapatite (HA) chromatography in bind‐and‐elute mode to purify HPV VLPs from host‐cell impurities such as proteins and nucleic acids, though binding capacity for VLPs is low due to mass transfer limitations related to their large particle size. The intent of this work was to utilize VLP disassembly prior to HA chromatography in order to increase column yield and capacity. Since L1 protein subunits demonstrated weaker binding avidity for HA resin compared to VLPs, this enabled flow‐through purification of L1 protein from strongly adsorbed host cell impurities. Mobile phase conditions were evaluated in batch partition screening experiments to determine the optimal conditions for L1 protein recovery with selective clearance of nucleic acid. Dynamic loading studies showed that while nucleic acid removal was equivalent to the VLP purification process, the flow‐through process with disassembled L1 protein achieved higher L1 yield and column capacity. Optimal conditions were applied to HA flow‐through purification for multiple HPV types with recombinant L1 protein expressed in yeast, demonstrating > 35% increased yield for six of eight types. The purified, disassembled proteins were subsequently reassembled and had comparable product attributes to the VLP purification process. The implementation of disassembly prior to purification also eliminates the requirement to perform a distinct final disassembly/reassembly process after isolating crude VLPs during purification.
- 16 August 2026
- Published by Wiley in Biotechnology and Bioengineering
Open AccessPurification of Disassembled Capsid Protein by Hydroxyapatite Chromatography Enhances Virus‐Like Particle Recovery
Virus‐like particles (VLPs) are a promising modality with extensive applications in prophylactic and therapeutic vaccine design. Human Papillomavirus (HPV) vaccines are one such example where VLP vaccine applications have led to the successful reduction in HPV‐associated diseases, such as cervical cancer. Current purification approaches utilize hydroxyapatite (HA) chromatography in bind‐and‐elute mode to purify HPV VLPs from host‐cell impurities such as proteins and nucleic acids, though binding capacity for VLPs is low due to mass transfer limitations related to their large particle size. The intent of this work was to utilize VLP disassembly prior to HA chromatography in order to increase column yield and capacity. Since L1 protein subunits demonstrated weaker binding avidity for HA resin compared to VLPs, this enabled flow‐through purification of L1 protein from strongly adsorbed host cell impurities. Mobile phase conditions were evaluated in batch partition screening experiments to determine the optimal conditions for L1 protein recovery with selective clearance of nucleic acid. Dynamic loading studies showed that while nucleic acid removal was equivalent to the VLP purification process, the flow‐through process with disassembled L1 protein achieved higher L1 yield and column capacity. Optimal conditions were applied to HA flow‐through purification for multiple HPV types with recombinant L1 protein expressed in yeast, demonstrating > 35% increased yield for six of eight types. The purified, disassembled proteins were subsequently reassembled and had comparable product attributes to the VLP purification process. The implementation of disassembly prior to purification also eliminates the requirement to perform a distinct final disassembly/reassembly process after isolating crude VLPs during purification.
- Open Access
- 10 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Mechanistic Investigation of Zn (II) Extraction and Interactions in Combination Biological Drug Products
Pre-filled syringes (PFS) and autoinjectors are increasingly used to deliver biologic drug products, particularly monoclonal antibodies (mAbs), to improve convenience, compliance and dosing accuracy. However, these systems face performance and quality challenges such as needle clogging, particularly for high concentration, viscous, and aggregation-prone formulations. The origins and mechanisms by which device-derived leachables influence clogging and protein stability remain poorly understood. In this study, we investigated zinc (Zn) leaching from rigid needle shields (RNS) and its interactions with a high concentration dupilumab formulation and common excipients. ICP-MS quantification shows that Zn was the predominant metal in RNS batches, and their extraction kinetics depended strongly on time, temperature, and the presence of a routinely utilized surfactant, polysorbate 80 (PS-80). Stressing RNS materials in the dupilumab formulation at 40°C for 14 days yielded up to 550 µg/mL Zn(II), roughly 100-fold above typical specifications. Isothermal titration calorimetry (ITC) revealed millimolar Zn(II) binding to PS‑80 and weaker interaction with buffer components (histidine, arginine, and acetate), which together promote Zn release. Structural modeling identified surface-exposed regions of dupilumab enriched in histidine, sulfur-containing, and carboxylic acid-containing residues that are geometrically arranged to chelate Zn(II), highlighting likely Zn(II) binding motifs. These protein-metal and excipient-metal interactions, along with PS-80 degradation catalyzed by Zn, correlate with increased solution viscosity and formation of high molecular weight species. Zn leaching from RNS and its synergistic interactions with PS80, buffer components, and the mAb can drive PS-80 degradation, increase viscosity, and promote higher-order protein aggregation, factors that plausibly contribute to needle clogging. Overall, Zn can simultaneously interact with proteins, increasing their propensity to aggregate while degrading the excipients intended to stabilize them against aggregation. Understanding these mechanisms can inform candidate selection, formulation design and device choice to mitigate protein aggregation and syringe clogging and improve product reliability and therapeutic outcomes.
- 10 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessMechanistic Investigation of Zn (II) Extraction and Interactions in Combination Biological Drug Products
Pre-filled syringes (PFS) and autoinjectors are increasingly used to deliver biologic drug products, particularly monoclonal antibodies (mAbs), to improve convenience, compliance and dosing accuracy. However, these systems face performance and quality challenges such as needle clogging, particularly for high concentration, viscous, and aggregation-prone formulations. The origins and mechanisms by which device-derived leachables influence clogging and protein stability remain poorly understood. In this study, we investigated zinc (Zn) leaching from rigid needle shields (RNS) and its interactions with a high concentration dupilumab formulation and common excipients. ICP-MS quantification shows that Zn was the predominant metal in RNS batches, and their extraction kinetics depended strongly on time, temperature, and the presence of a routinely utilized surfactant, polysorbate 80 (PS-80). Stressing RNS materials in the dupilumab formulation at 40°C for 14 days yielded up to 550 µg/mL Zn(II), roughly 100-fold above typical specifications. Isothermal titration calorimetry (ITC) revealed millimolar Zn(II) binding to PS‑80 and weaker interaction with buffer components (histidine, arginine, and acetate), which together promote Zn release. Structural modeling identified surface-exposed regions of dupilumab enriched in histidine, sulfur-containing, and carboxylic acid-containing residues that are geometrically arranged to chelate Zn(II), highlighting likely Zn(II) binding motifs. These protein-metal and excipient-metal interactions, along with PS-80 degradation catalyzed by Zn, correlate with increased solution viscosity and formation of high molecular weight species. Zn leaching from RNS and its synergistic interactions with PS80, buffer components, and the mAb can drive PS-80 degradation, increase viscosity, and promote higher-order protein aggregation, factors that plausibly contribute to needle clogging. Overall, Zn can simultaneously interact with proteins, increasing their propensity to aggregate while degrading the excipients intended to stabilize them against aggregation. Understanding these mechanisms can inform candidate selection, formulation design and device choice to mitigate protein aggregation and syringe clogging and improve product reliability and therapeutic outcomes.